Skip to main content

Table 1 Characteristics of included randomised controlled trials

From: Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis

    

Patients

 

Study

Design

Treatment groups

APACHE II score

N

Age (Y)

Male/female

Intervention

Nelson 1998 [37]

2 parallel groups, 71 centers

G-CSF

16.1

380

63.4 ± 16.4

235/145

Filgrastim: 300 μg/d, subcutaneous, 10 days

  

Placebo

17.0

376

64.5 ± 15.2

254/122

 

Nelson 2000 [38]

2 parallel groups, 105 centers

G-CSF

14.5

237

61.1 ± 17.3

138/99

Filgrastim: 300 μg/d, subcutaneous, 10 days

  

Placebo

15.5

243

62.3 ± 17.4

153/90

 

Tanaka 2001 [39]

2 parallel groups, 1 center

G-CSF

18.0

12

49.8 ± 6.4

11/1

Lenograstim: 2 μg/kg/d, intravenous, 5 days

  

Placebo

15.9

13

54.8 ± 5.7

9/4

 

Wund 2001 [40]

2 parallel groups, 3 centers

G-CSF

25.0

12

49.5

8/4

Filgrastim: 300 μg/d, intravenous, 10 days

  

Placebo

31.5

6

56.5

4/2

 

Presneill 2002 [41]

2 parallel groups, 1 center

GM-CSF

12

10

62

7/3

Molgramostim:3 μg/kg/d, intravenous, 5 days

  

Placebo

10

8

46.5

6/2

 

Root 2003 [42]

2 parallel groups, 96 centers

G-CSF

24.3 ± 7.5

348

58.9 ± 17.1

240/108

Filgrastim: 300 μg/d, intravenous, 5 days

  

Placebo

24.2 ± 6.9

353

60.0 ± 16.4

247/106

 

Hartma 2005 [43]

2 parallel groups, 1 center

G-CSF

13

13

66

2/11

Filgrastim: 300 μg/d, subcutaneous, 7 days

  

Placebo

12.5

16

63

5/11

 

Rosen 2005 [44]

2 parallel groups, 1 center

GM-CSF

_

18

56

8/10

Sargramostim: 3 μg/kg/d, intravenous, 3 days

  

Placebo

_

15

52

9/6

 

Orozco 2006 [45]

2 parallel groups, 1 center

GM-CSF

7.3 ± 6.3

28

43.2 ± 15.9

13/15

Molgramostim: 3 μg/kg/d, subcutaneous, 4 days

  

Placebo

7.7 ± 6.4

30

49.2 ± 16.5

16/14

 

Cheng 2007 [46]

2 parallel groups, 1 center

G-CSF

22

30

61

_

Lenograstim: 263 μg/d, intravenous, 3 days

  

Placebo

22

30

57

_

 

Stephens 2008 [47]

2 parallel groups, 1 center

G-CSF

22.5 ± 7.6

81

51.0 ± 15.1

45/36

Lenograstim: 263 μg/d, intravenous, 10 days

  

Placebo

23.4 ± 8.2

83

48.9 ± 16.1

45/38

 

Meisel 2009 [48]

2 parallel groups, 3 centers

GM-CSF

21.3 ± 6.1

19

64.0 ± 13.6

16/3

GM-CSF: 4 μg/kg/d, subcutaneous, 8 days

  

Placebo

22.5 ± 6.6

19

63.3 ± 14.2

15/4

Â